Stoke, Personalis set terms for NASDAQ IPOs

Stoke and Personalis set similar ranges for their NASDAQ IPOs Friday, which could raise a combined total of $200 million.

Genetic diseases company Stoke Therapeutics Inc. (Bedford, Mass.) and cancer genomics company Personalis Inc. (Menlo Park, Calif.) both proposed to sell 6.7 million shares at $14-$16 (see "New IPO Filings Include BridgeBio, Dermavant, Prevail, Atreca, Akero")...